Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the omega-3 fatty acid emulsion
(Omegaven®), when used in place of the conventional soy-based fat emulsion (Intralipid), is
effective in treating parenteral nutrition associated liver disease (PNALD) in children.
The study hypothesis is that Omegaven® can be safely provided to children who are dependent
on parenteral nutrition and have PNALD, and can reverse or prevent progression of PNALD until
the child can take adequate nutrition by mouth.